RIM
BMY.RT

Regent Investment Management’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Regent Investment Management’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-21,188
Closed -$15K – 210
2020
Q4 		$15K Sell
21,188
-460
-2% -$980 ﹤0.01% 194
2020
Q3 		$49K Sell
21,648
-2,060
-9% -$5.88K 0.02% 187
2020
Q2 		$85K Sell
23,708
-250
-1% -$902 0.03% 181
2020
Q1 		$91K Sell
23,958
-11,670
-33% -$38.4K 0.04% 172
2019
Q4 		$107K Buy
+35,628
New +$92.6K 0.03% 206

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.82B AUM
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return

Regent Investment Management's BMY.RT Position: Q1 2021 in Review

Regent Investment Management sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 21,188 shares — an estimated $15K sold.

Regent Investment Management first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $107K in Q4 2019. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Regent Investment Management reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Regent Investment Management sold 21,188 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $15K.
  • Regent Investment Management first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • Regent Investment Management's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $107K in Q4 2019.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Regent Investment Management's 13F filing for Q1 2021, filed 20 Apr 2021.